Citizens Reiterates Market Outperform on Bicara Therapeutics, Maintains $31 Price Target

Citizens analyst Reni J. Benjamin has reiterated a Market Outperform rating on Bicara Therapeutics (NASDAQ: BCAX) and maintained a price target of $31 for the stock.